Tricor

Fenofibrate

Intended to address high lipid levels.

Active ingredient
Fenofibrate
Supply
Pharmacy
Route
Oral use
Form
Tablet
Strengths
160 · 200mg

Tricor details

Alternative names
Lipantil; Supralip
Therapeutic class
Fibrate
Pharmacological class
PPAR-alpha agonist
Contraindications
severe hepatic impairment; severe renal impairment; gallbladder disease
Precautions and warnings
monitor liver enzymes; report unexplained muscle pain
Minor side effects
nausea; diarrhoea; abdominal pain
Moderate side effects
rash; elevated liver enzymes
Serious side effects
rhabdomyolysis, requires immediate medical attention
Dosage forms
Tablet
Administration route
Oral use
Patient summary
intended to address high lipid levels.
Supply category
Pharmacist only, dispensed without a prescription
Manufacturer
AbbVie
Onset Time
2–4 weeks
Duration
24 hours
Storage instructions
Store in a cool, dry place.
Drug interactions
statins; warfarin
Age restrictions
Not recommended for children.
Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Not recommended.
Mechanism of action

Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), which increases the breakdown of triglycerides and lowers LDL cholesterol levels.

Where this medicine is registered

  • Singapore
  • Hong Kong
  • Thailand
  • Malaysia
  • Philippines
  • Indonesia
  • Taiwan
  • South Korea
  • Japan
  • Australia
  • New Zealand
  • UAE
  • South Africa

About Tricor

Tricor is a well-known brand of fenofibrate, a medication used to manage hypertriglyceridaemia and mixed dyslipidaemia. This active ingredient is also sold under alternative names such as Lipantil and Supralip. Produced by AbbVie, the medication is available in tablet form in strengths of 160mg and 200mg.

Buying Tricor online

Tricor is registered across 13 markets, including Indonesia, Taiwan and South Korea, with availability also in Japan, the UAE and Singapore. For expats and residents living far from a well stocked pharmacy, ordering online provides consistent access to standard lipid management treatments. Generic fenofibrate, much of which is manufactured in India, remains a highly affordable alternative to the original brand, keeping therapy accessible for patients across the region.